09/07/20 -"Taking into account the recent trading update of one of Elior's major rivals, we are convinced that the health crisis may not have such a severe impact in the near term and that a recovery may take ..."
Pages
52
Language
English
Published on
09/07/20
You may also be interested by these reports :
25/12/25
We have realigned our NAV valuation, which is now distributed across 3 businesses – UK, US and International, each valued using the EV/EBITDA ...
17/12/25
When we last highlighted Entain (BUY ; UK) around 14 months ago, our optimism was driven by its operational recovery and strong organic growth, with ...
16/12/25
We adopt a more conservative stance on Entain’s medium- to long-term outlook, reflecting (a) the company’s absence from the lucrative ...
11/12/25
We have incorporated the impact of the recently announced budget, resulting in a decline of c.16% in our DCF valuation and c.14% in NAV. ...